Find all the latest information
, arranged by types, translocations, and mutations.
Listed below are recently updated categories.
Real-world experience with ruxolitinib in myelofibrosis
Ruxolitinib is a Janus kinase (JAK) 1 and JAK 2 inhibitor approved for primary and secondary intermediate-/high-risk myelofibrosis (MF). The...
U.S. FDA grants orphan drug designation for PTG-300 for the treatment of polycythemia vera
PTG-300, an injectable hepcidin mimetic peptide, has received orphan drug designation by the U.S. Food and...
Calreticulin haploinsufficiency is needed for the indication of MPN-like pathology in vitro
Mutant CALR has been shown to bind to MPL and activate downstream signaling pathways that lead to the...
Promising preclinical data on selective HDAC11 inhibition and MPN improvement
During the 61st American Society of Hematology (ASH) Annual Meeting & Exposition (2019), Vasundhara Sharma presented...
Fedratinib in myelofibrosis
Fedratinib is a pyrimidine-based Janus kinase 2 (JAK2) inhibitor currently licenced by the U.S. Food and Drug Administration (FDA) for the treatment of adults with...
Increased a5β1 integrin adhesion to fibronectin contributes to megakaryocytosis in primary myelofibrosis models
Shinobu Matsuura and colleagues investigated the role of fibronectin and its main...
Ruxolitinib failure management algorithm for myelofibrosis: Canadian MPNG consensus
There is currently limited agreement on how to define ruxolitinib failure or intolerance. The Canadian MPN Group...
TET2 mutations predict thrombotic risk in patients with polycythemia vera
There is limited data on the role of DTA mutations in the prediction of thrombotic risk in patients with MPN. For...
Epigenetic modifier mutations
JAK2 driver mutations
JAK2 exon 12 deletions
JAK2 exon 12 insertions
MPL driver mutations
Chronic eosinophilic leukemia
Chronic neutrophilic leukemia
Tumor suppressor mutations